What does Elicio Therapeutics, Inc. do?
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog…
What is Elicio Therapeutics, Inc.'s P/E and P/B ratio?
Elicio Therapeutics, Inc. has a P/E ratio of -0.9 and a P/B ratio of 6.62.
What is Elicio Therapeutics, Inc.'s debt-to-equity ratio?
Elicio Therapeutics, Inc. has a debt-to-equity ratio of 1.78.
How much does Elicio Therapeutics, Inc. owe compared with what it owns?
Elicio Therapeutics, Inc. owes $0.75 for every $1 it owns (balance sheet Jun 2026), which is moderate.
What is Elicio Therapeutics, Inc.'s Positivity rank?
Elicio Therapeutics, Inc. is ranked #4,529 of 6,775 companies globally and #2,276 of 4,000 in United States on PositoAI, with a Positivity Score of 19,346.
Does Elicio Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Elicio Therapeutics, Inc..
Where can I read the latest news about Elicio Therapeutics, Inc.?
Recent headlines about Elicio Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Elicio Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Elicio Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.